{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:25:50Z","timestamp":1790652350244,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01343-4","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T14:47:28Z","timestamp":1755182848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"given":"Tara","family":"Sebastian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3458-824X","authenticated-orcid":false,"given":"Sridevi","family":"Rajeeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasmin","family":"Farzana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Firestone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jurgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-4498","authenticated-orcid":false,"given":"Bruno Almeida","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Lesokhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7922-2594","authenticated-orcid":false,"given":"Carlyn Rose","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":false,"given":"Gunjan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-4318","authenticated-orcid":false,"given":"Neha","family":"Korde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-1189","authenticated-orcid":false,"given":"Heather","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2036-1749","authenticated-orcid":false,"given":"Hani","family":"Hassoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-4854","authenticated-orcid":false,"given":"Kylee","family":"Maclachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8419-1091","authenticated-orcid":false,"given":"Urvi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9045-6495","authenticated-orcid":false,"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-8493","authenticated-orcid":false,"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6971-1408","authenticated-orcid":false,"given":"David","family":"Nemirovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-8731","authenticated-orcid":false,"given":"Saad","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2815-9561","authenticated-orcid":false,"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4129-5867","authenticated-orcid":false,"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"1343_CR1","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266\u201375.","journal-title":"Leukemia"},{"key":"1343_CR2","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","volume":"21","author":"S Usmani","year":"2016","unstructured":"Usmani S, Ahmadi T, Ng Y, Lam A, Desai A, Potluri R, et al. Analysis of real-world data on overall survival in multiple myeloma patients with \u22653 prior lines of therapy including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;21:1355\u201361.","journal-title":"Oncologist"},{"key":"1343_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335\u201347.","journal-title":"N Engl J Med"},{"key":"1343_CR4","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002\u201314.","journal-title":"N Engl J Med"},{"key":"1343_CR5","doi-asserted-by":"publisher","first-page":"5266","DOI":"10.1182\/blood-2022-158270","volume":"140","author":"A Girvan","year":"2022","unstructured":"Girvan A, Yu J, Emechebe N, Kamalakar R, Luo Y. Real-world treatment patterns and outcomes of Daratumumab retreatment in multiple myeloma in the United States. Blood. 2022;140:5266\u20137.","journal-title":"Blood"},{"key":"1343_CR6","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e46.","journal-title":"Lancet Oncol"},{"key":"1343_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biology Blood Marrow Transplant"},{"key":"1343_CR8","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","volume":"42","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, et al. Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:1665\u201375.","journal-title":"J Clin Oncol"},{"key":"1343_CR9","first-page":"1514","volume":"109","author":"H Hashmi","year":"2024","unstructured":"Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, et al. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica. 2024;109:1514\u201324.","journal-title":"Haematologica"},{"key":"1343_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","volume":"17","author":"S Zanwar","year":"2024","unstructured":"Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, et al. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol Oncol. 2024;17:42.","journal-title":"J Hematol Oncol"},{"key":"1343_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01068-w","volume":"14","author":"D Dima","year":"2024","unstructured":"Dima D, Abdallah AO, Davis JA, Awada H, Goel U, Rashid A, et al. Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy. Blood Cancer J. 2024;14:90.","journal-title":"Blood Cancer J"},{"key":"1343_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023;13:117.","journal-title":"Blood Cancer J"},{"key":"1343_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12:868.","journal-title":"Nat Commun"},{"key":"1343_CR14","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29:2295\u2013306.","journal-title":"Nat Med"},{"key":"1343_CR15","unstructured":"Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, et al. Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma. J Clin Oncol. 2025:43:1597\u20131609."}],"updated-by":[{"DOI":"10.1038\/s41408-025-01383-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000}}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01343-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01343-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01343-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T18:03:54Z","timestamp":1760465034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01343-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1343"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01343-4","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41408-025-01383-w","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In this article the author names have been updated. They have been now written out in full.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41408-025-01383-w","URL":"https:\/\/doi.org\/10.1038\/s41408-025-01383-w","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AL reports nonfinancial support from Pfizer; grants and personal fees from Janssen, outside the submitted work; serves on the Data Safety Monitoring Board for ArcellX and also has a patent US20150037346A1 with royalties paid. CT reports research funding from Janssen and Takeda, personal fees from MJH Life Sciences, and has received honoraria for consultancy\/participated in the advisory boards for Janssen and Sanofi. GS receives research funding from Janssen, Amgen, BMS, Beyond Spring; serves on the data safety monitoring board (DSMB) for ArcellX; and receives research funding to the institution from Janssen, Amgen, BMS, Beyond Spring, and GPCR. NK reports research funding through Amgen, Janssen, Epizyme, AbbVie; consults for Clinical Care Options, OncLive, and Intellisphere Remedy Health; and participated in advisory board for Janssen and MedImmune. HL has served as a paid consultant for AbbVie, Immix Biopharma, Legend Biotech, Alexion, Prothena, and has received research funding from Nexcella, Janssen, Alexion, Protego, and Prothena. MS served as a paid consultant for McKinsey & Company, Angiocrine Bioscience, Inc., and Omeros Corporation; received research funding from Angiocrine Bioscience, Inc., Omeros Corporation, Amgen Inc., Bristol Myers Squibb, and Sanofi; served on ad hoc advisory boards for Kite - A Gilead Company, and Miltenyi Biotec; and received honoraria from i3Health, Medscape, CancerNetwork, and IDEOlogy. HH reports grants from Celgene, Takeda, and Janssen, outside the submitted work. KM reports grant support from ASH, MMRF, and IMS. U.A.S. reports research support from Celgene\/Bristol Myers Squibb and Janssen; personal fees from ACCC, MashUp MD, Janssen Biotech, Sanofi, Bristol Myers Squibb, MJH LifeSciences, Intellisphere, Phillips Gilmore Oncology Communications, i3 health, and RedMedEd; and nonfinancial support from the ASH Clinical Research Training Institute and TREC Training Workshop (R25CA203650; PI: Melinda Irwin). MH reports research funding from GlaxoSmithKline, BeiGene, AbbVie, and Daiichi Sankyo, and has received honoraria for consultancy\/participated in the advisory boards for Curio Science LLC, Intellisphere LLC, Bristol Myers Squibb, Janssen and GlaxoSmithKline. SG reports personal fees and advisory role (scientific advisory board) from Actinium, Celgene, Bristol Myers Squibb, Sanofi, Amgen, Pfizer, GlaxoSmithKline, JAZZ, Janssen, Omeros, Takeda, and Kite, outside the submitted work. SZU received research funding from Amgen, AbbVie, Array Biopharma, BMS, Celgene, Gilead, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda, is a Consultant to AbbVie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Gracell, Janssen, Oncopeptides, Pfizer, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio, and is also a Speaker with Amgen, BMS, Janssen, Sanofi. Bristol Myers Squibb, Sanofi, Amgen, Pfizer, GlaxoSmithKline, JAZZ, Janssen, Omeros, Takeda, and Kite, outside the submitted work. S.M. reports research funding from the NCI, Janssen Oncology, Bristol Myers Squibb, Allogene Therapeutics, Fate Therapeutics, Caribou Therapeutics, and Takeda Oncology and has received consulting fees from EviCore, Optum, BioAscend, Janssen Oncology, Bristol Myers Squibb, AbbVie, HMP Education, and Legend Biotech, and honoraria from OncLive, Physician Education Resource, MJH Life Sciences, and Plexus Communications. H.H. reports consultancy for Karyopharm, Amgen, and Janssen. TS, SR, TF, RF, EJ, KM, BC, AD, and DN, have no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}